-
A Breakthrough for Circadian Rhythm: Vanda Pharmaceuticals Reports Positive Phase III Results
New Hope for Delayed Sleep-Wake Phase Disorder Vanda Pharmaceuticals has reached a significant milestone in sleep medicine. The company recently announced positive results from its Phase III clinical trial evaluating Hetlioz (tasimelteon) for the treatment of Delayed Sleep-Wake Phase Disorder (DSWPD). Understanding DSWPD Delayed Sleep-Wake Phase Disorder is a chronic circadian rhythm disorder characterized by…
-
New Breakthrough: Takeda’s Oveporexton Shows Promise for Sleep and Daily Function
NYSE: $TAK A Potential Leap Forward in Sleep Research Recent clinical trial data released by Takeda has highlighted promising results for their investigational therapy, oveporexton. Designed to address the complexities of sleep disorders, the study focused on how this treatment impacts both nighttime rest and daytime cognitive performance. Key Study Findings The pivotal study evaluated…